International Clinical Trial: Zinc Sulfate Enhances the Efficacy and Safety of Toripalimab Combined with Disitamab Vedotin in the Treatment of Patients with HER2-Positive Muscle-Invasive Bladder Urothelial Carcinoma

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128788) titled 'Zinc Sulfate Enhances the Efficacy and Safety of Toripalimab Combined with Disitamab Vedotin in the Treatment of Patients with HER2-Positive Muscle-Invasive Bladder Urothelial Carcinoma' on July 26.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Condition: bladder cancer

Intervention: Control group:Disitamab Vedotin targeted therapy combined with Toripalimab Immunotherapy, the regimen is the same as in the zinc?supplemented group. Zinc supplementation group:Disitamab Vedotin targeted therapy comb...